{"id":626016,"date":"2024-06-29T01:10:02","date_gmt":"2024-06-28T22:10:02","guid":{"rendered":"https:\/\/en.buradabiliyorum.com\/clinical-response-seen-for-patients-with-severe-asthma-initiating-biologics\/"},"modified":"2024-06-29T01:10:02","modified_gmt":"2024-06-28T22:10:02","slug":"clinical-response-seen-for-patients-with-severe-asthma-initiating-biologics","status":"publish","type":"post","link":"https:\/\/buradabiliyorum.com\/en\/clinical-response-seen-for-patients-with-severe-asthma-initiating-biologics\/","title":{"rendered":"#Clinical response seen for patients with severe asthma initiating biologics"},"content":{"rendered":"
\n
\n
\n
\"Clinical<\/figure>\n<\/div>\n<\/div>\n

Patients with severe asthma initiating biologics exhibit clinical responses and super-responses, but 40 to 50% do not meet response criteria, according to a study published<\/a> online June 22 in Allergy<\/i>.<\/p>\n

Eve Denton, M.B.B.S., from Alfred Health in Melbourne, Australia, and colleagues examined responsiveness to biologics in a real-world population of adults with severe asthma. Participants in the International Severe Asthma Registry (ISAR) with \u226524\u2009weeks of follow-up were categorized as those who initiated or did not initiate biologics.<\/p>\n

Treatment responses were examined in various domains: forced expiratory volume in one\u2009second (FEV1<\/sub>) increase by \u2265100\u2009mL, improved asthma control, annualized exacerbation rate (AER) reduction \u226550%, and any long-term oral corticosteroids (LTOCS) dose reduction. Overall, 5.3% of the patients in ISAR met the inclusion criteria for the trial; 2,116 of 8,451 initiated biologics.<\/p>\n

The researchers found that compared with noninitiators, biologic initiators had worse baseline impairment, despite having similar biomarker levels. Of the initiators, about half or more had treatment responses: 59% AER reduction, 54% FEV1<\/sub> increase, 49% improved control, and 49% reduced LTOCS; of these, 32, 19, 30, and 39%, respectively, were super-responses. Compared with noninitiators, biologic initiators more often had responses\/super-responses; however, about 40 to 50% of initiators did not meet the criteria for response.<\/p>\n

“These findings justify further research to determine whether initiating biologics earlier\u2014before asthma causes irreversible lung damage\u2014may increase the likelihood of achieving a response or super-response,” the authors write.<\/p>\n

Several authors disclosed ties to biopharmaceutical companies, including AstraZeneca and Optimum Patient Care Ltd., which funded the study.<\/p>\n

\n More information:<\/strong>
\n Eve Denton et al, Real\u2010world biologics response and super\u2010response in the International Severe Asthma Registry cohort, Allergy<\/i> (2024). DOI: 10.1111\/all.16178<\/a><\/p><\/div>\n

\u00a9 2024 HealthDay<\/a>. All rights reserved.<\/p>\n

<\/p>\n

\n

Citation<\/strong>:
\n Clinical response seen for patients with severe asthma initiating biologics (2024, June 28)
\n retrieved 29 June 2024
\n from https:\/\/medicalxpress.com\/news<\/a>\/2024-06-clinical-response-patients-severe-asthma.html<\/p>\n

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
\n part may be reproduced without the written permission. The content is provided for information purposes only.<\/p><\/div>\n<\/p><\/div>\n